The plasma lecithin:cholesterol acyltransferase (LCAT) activity was followed during the course of acute parenchymatous liver disease in 10 patients. Marked reduction was found in patients with serious liver failure. Increase in plasma LCAT activity was observed concomitant with clinical improvement. The reduced plasma LCAT activity may explain the low concentrations of plasma cholesterol esters in these patients. The findings suggest that the plasma LCAT activity is dependent on liver parenchymal function and indicate hepatocellular origin of this plasma enzyme.
No takes yet. Share an insight, caveat, or question.
Gjone et al. (1971) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: